For two decades India bought most of its medical technology from abroad. The government's own assessment put import dependence at more than 85% of the market in 2020, and the country's role was that of a large consumer rather than a producer. That position is now changing, as incentive schemes, multinational localization, and domestic innovation turn the Indian medical devices sector into a manufacturing and export base.
According to IMARC Group, the India Medical Devices Market size reached USD 19.11 Billion in 2025, rose to USD 20.23 Billion in 2026, and is projected to reach USD 31.85 Billion by 2034, growing at a CAGR of 5.83% (2026–2034). The inflection shows up on the export side as well: medical device exports grew from USD 2,532 Million in FY2020-21 to USD 4,014 Million in FY2024-25.
Demand fundamentals are durable. India has 101 Million people with diabetes, around 70,000 registered hospitals, over 1,200 cardiac catheterization laboratories as of 2024, and more than 600 ambulatory surgical centres growing at 18–20% annually, with medical tourism worth a USD 9 Billion opportunity.
This blog provides an India Medical Devices Market analysis covering segments, recent announcements, trends, regional hotspots, competitive strategies, policy and risks, and the long-range outlook for manufacturers, investors, and health systems.
Key Takeaways
According to IMARC Group, demand concentrates in high-volume surgical and diagnostic categories purchased mainly by institutional buyers. The India Medical Devices Market share across the leading segments breaks down as follows:
Growth of roughly 5.83% a year understates the structural change underneath, because the composition of supply is shifting from imported finished devices to locally manufactured ones.
Scheme disbursements, platform launches, and clinical scale-ups have all moved in the past 18 months:
The pattern is consistent: Indian facilities are increasingly where global platforms launch, build, and clinically validate, not just where they sell.
Three trends are transforming the medical devices market in India:
1. AI-Enabled Imaging, Diagnostics, and Connected Devices
Imaging and diagnostics are being rebuilt around algorithms and continuous data rather than single readings. Diagnostic imaging already holds 14.0% of revenue, and in-vitro diagnostics and diabetes care add a further 20.0%, the categories where artificial intelligence and wearable sensors land first. Abbott's FreeStyle Libre 2 Plus, launched in August 2025, delivers automatic glucose readings that feed digital care pathways, while the Ayushman Bharat Digital Mission crossed 90 crore health accounts by May 2026, creating the record layer that connected devices can write into.
2. Robotic and Minimally Invasive Surgical Systems
Surgical robotics has moved from pilot installations to routine use. SS Innovations' installed base reached 238 systems with 14,103 procedures by September 2026, including 258 pediatric robotic surgeries and 188 telesurgery procedures, with the longest telesurgery spanning more than 13,600 miles between Colombia and India. Domestically engineered platforms at lower price points make robotic surgery viable outside metro tertiary hospitals, and with hospitals and surgical centres accounting for 70.0% of demand, adoption follows hospital capital cycles.
3. Domestic Manufacturing and Medical Device Parks
Localization is the structural trend. The production-linked incentive scheme, with a Rs. 3,420 crore outlay running from FY2022-23 to FY2026-27 and 28 approved applicants, has seen 24 greenfield projects commissioned and production start for 57 products including linear accelerators, MRI machines, ultrasound systems, CT scanners, and X-ray equipment. Three medical device parks have been approved at Greater Noida, Ujjain, and Kanchipuram, with project costs above Rs. 871.11 crore, central assistance of Rs. 100 crore per park, and Rs. 210 crore already released. India Medical Devices Market trends now hinge on how much of this capacity converts into export-grade output.
South India leads with a 34.0% share and is the fastest-growing region, followed by North India at 28.0%, West India at 22.0%, and East India at 16.0%. The southern states combine hospital density, a large private tertiary care network, and most inbound medical travel, supporting demand for imaging, orthopedic, and cardiovascular devices.
Manufacturing and research footprints are spreading wider. The approved medical device parks place dedicated infrastructure in Uttar Pradesh, Madhya Pradesh, and Tamil Nadu, while Siemens Healthineers has committed about EUR 200 Million to an integrated campus in Bengaluru alongside Rs. 91.9 crore for local computed tomography and magnetic resonance manufacturing, and Philips has invested Rs. 750 crore across a Pune research centre and a Bengaluru innovation campus. Medtronic, Boston Scientific, GE HealthCare, and Stryker have also expanded engineering operations in Bengaluru and Hyderabad, making the south a design hub as well as the largest market.
The top 10 companies account for approximately 40–50% of market revenue in 2025, leaving substantial room for domestic challengers in value segments. Strategies divide between multinationals localizing production and Indian firms building clinically validated platforms. Key players include:
The competitive question for the next cycle is whether localized multinational plants or domestic platform builders capture the export opportunity first.
Government policy is the main lever shaping medical device market access in India:
Key challenges and risks include:
IMARC Group projects the market to grow from USD 20.23 Billion in 2026 to USD 31.85 Billion by 2034, a CAGR of 5.83% (2026–2034). Three streams carry that growth: hospital capital spending, chronic disease management devices, and exports from newly commissioned plants.
The future of the medical device industry in India depends on moving up the value chain. Exports have already climbed to USD 4,014 Million in FY2024-25 and locally made linear accelerators, MRI machines, and CT scanners are now in production, which is the step that separates a consumption hub from a manufacturing base. Investment opportunities concentrate in high-end imaging, surgical robotics, diagnostics, and components, where import substitution has the furthest to run.
India is no longer only a destination for medical technology; it is becoming a place where devices are engineered, manufactured, and exported. Production-linked incentives have commissioned plants for equipment the country once bought entirely from abroad, a domestically built surgical robot is operating across 12 countries, and a nationwide digital health backbone is in place, with the market forecast to grow at a CAGR of 5.83% (2026–2034).
For manufacturers, the priority is to convert approved capacity into export-grade, certified output. For investors, the value lies in high-end categories where import substitution is still unfinished. For policymakers, faster approvals and a pricing framework that rewards innovation will decide how far India climbs in the global MedTech order.
Have a question or need assistance?
Please complete the form with your inquiry or reach out to us at
Phone Number
+91-120-433-0800